Subscribe To
Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights
On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023 Submitted protocol amendment to regulatory authorities for Imagine-1 study for GM1 gangliosidosis to treat patients at a third, higher dose; expect to dose first patient at Dose 3 in second half of […] The post Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights appeared first on ForexTV...
Read More
Posted: May 11 2023, 11:00
Author Name: forextv
Views: 111572